European Medicines Agency

Doc. Ref. EMEA/626873/2008
P/124/2008

EUROPEAN MEDICINES AGENCY DECISION

of 5 December 2008

on the application for agreement of a Paediatric Investigation Plan for everolimus (Certican and associated names) EMEA-000019-PIP02-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 5 December 2008

on the application for agreement of a Paediatric Investigation Plan for everolimus (Certican and associated names) EMEA-000019-PIP02-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Ltd on 7 February 2008 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 October 2008, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given a positive opinion,

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for everolimus (Certican and associated names), tablet and dispersible tablet, oral use the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for everolimus (Certican and associated names), tablet and dispersible tablet, oral use the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB Horsham.

Done at London, 5 December 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref.: EMEA/626873/2008
EMEA-000019-PIP02-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A REQUEST FOR AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN FOR

Scope of the application

Active substance:
Everolimus

Invented name:
Certican and associated names

Condition(s):
Subependymal giant cell astrocytoma
Angiomyolipoma

Pharmaceutical form(s):
Tablet
Dispersible tablet

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Novartis Europharm Ltd

Information about the authorised medicinal product:
See Annex II

Basis for opinion

Pursuant to Article 16.1 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd submitted for agreement to the EMEA on 07 February 2008 a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 13 March 2008.

Supplementary information was provided by the applicant on 14 August 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended and concluded in accordance with
  Article 11(1)(b) of Regulation (EC) No 1901/2006 as amended, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix(ces).

London, 17 October 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Subependymal giant cell astrocytoma
Angiomyolipoma

B. WAIVER

- **Condition**

Angiomyolipoma

The waiver applies to:

All subsets of the paediatric population from birth to less than 18 years of age

for tablet for oral use and dispersible tablet for oral use

on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Subependymal giant cell astrocytoma

- **Proposed PIP indication**

Treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC)

- **Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years

- **Formulation(s)**

Tablet for oral use
Dispersible tablet for oral use

- **Studies**

Area	Number of studies	Description
Quality	-	Not applicable
Non-clinical	-	Not applicable
Clinical	3	Randomized, double-blind, placebo-controlled, parallel-group, dose-titration, comparative, multi-centre study to evaluate pharmacokinetics, safety, tolerability and activity of everolimus in children from birth to less than 18 years of age Relative bioavailability study between intact 1 mg tablet and 1 mg tablet dispersed in water in adults Bioequivalence study between intact 1 mg tablet and 2 mg dispersible tablet in adults

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	**Yes**
Date of completion of the paediatric investigation plan:	**By October 2011**
Deferral for initiation of some or all studies contained in the paediatric investigation plan:	**No**
Deferral for completion of some or all studies contained in the paediatric investigation plan:	**No**

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

Invented Name	Pharmaceutical Form	Route of administration
Certican and associated names	Dispersible tablet	Oral use
Certican and associated names	Tablet	Oral use